Benzinga's Top #PreMarket Gainers
Exelixis (NASDAQ: EXEL) shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial.
Progenics Pharmaceuticals (NASDAQ: PGNX) shares surged 11.08% to $4.71 in pre-market trading. Salix Pharmaceuticals (NASDAQ: SLXP) and Progenics reported that the FDA Office of Drug Evaluation III has approved Salix request for the FDA approval of RELISTOR sNDA.
Mylan (NASDAQ: MYL) shares gained 3.59% to $52.00 in pre-market trading after the company announced its plans to acquire Abbott's (NYSE: ABT) non-U.S. developed markets specialty and branded generics business in a $5.3 billion all-stock transaction.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.